Bailard’s Protalix BioTherapeutics PLX Stock Holding History

Bailard’s Portfolio PLX Stock Details PLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-68,100	Closed	-$121K	–	794
2023 Q4	$121K	Buy	+68,100	New	+$106K	﹤0.01%	679

Other funds holding PLX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Bailard's PLX Position: Q1 2024 in Review

Bailard sold out of Protalix BioTherapeutics (PLX) in Q1 2024, closing a stake of 68,100 shares — an estimated $121K sold.

Bailard first reported a position in PLX in Q4 2023 and held it in 1 quarter. The position peaked at $121K in Q4 2023. 63 funds tracked by Wall St. Rank hold PLX as of Q1 2024.

Bailard reported no remaining Protalix BioTherapeutics position as of Q1 2024 after selling out during the quarter.
Bailard sold 68,100 Protalix BioTherapeutics shares in Q1 2024, an estimated $121K.
Bailard first reported a position in Protalix BioTherapeutics in Q4 2023 and held it in 1 quarter.
Bailard's Protalix BioTherapeutics position peaked at $121K in Q4 2023.
63 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q1 2024.

Based on Bailard's 13F filing for Q1 2024, filed 8 May 2024.